A Phase 1b Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2018
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Oxaliplatin; Rituximab
- Indications B-cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Acronyms BIBLOS
- 09 Oct 2018 Status changed from recruiting to discontinued.
- 05 Jun 2018 Results (n=12) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 18 Apr 2018 Results of Population pharmacokinetic modeling of ibrutinib presented at the 109th Annual Meeting of the American Association for Cancer Research